Research guide · Metabolic Support
Tirzepatide — research protocol
Dual agonist compound studied for advanced metabolic and weight management protocols.
This guide summarizes study areas and sources associated with the compound. BioPeptideX does not convert experimental information into a clinical regimen or recommend an individual dose, frequency, route or duration.
Catalog presentations
Concentration table
Mathematical reference only; this is not a dosing recommendation.
Research areas
- GIP/GLP-1 dual agonist
- Lyophilized stability
- Independent COA available
Most-cited research protocols
Educational information based on research protocols and literature; it does not replace guidance from a healthcare professional.
Tirzepatide is a once-weekly injection that activates two appetite and blood-sugar hormones: GIP and GLP-1. It is approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea.
| Dose | Frequency | Duration | Route | |
|---|---|---|---|---|
| Phase 1 — Initiation | 2.5 mg | once weekly | Weeks 1–4 | Subcutaneous |
| Phase 2 — Early maintenance | 5 mg | once weekly | Weeks 5–8 | Subcutaneous |
| Phase 3 — Mid escalation | 7.5 mg | once weekly | Weeks 9–12 | Subcutaneous |
| Phase 4 — Mid maintenance | 10 mg | once weekly | Weeks 13–16 | Subcutaneous |
Cycle: Each dose step lasts at least 4 weeks to allow blood levels to stabilize.
Benefits and research observations: Expect mild appetite reduction and potential nausea in early weeks, progressing to more pronounced appetite and weight changes by week 12-16. Monitor weight, HbA1c (for T2D), blood pressure, heart rate, and symptoms of severe side effects.
Handling and storage
Store unreconstituted product according to its label and maintain the cold chain where applicable. After any preparation, follow only validated instructions for the specific product and diluent. Do not use if packaging is damaged or the solution shows particles or unexpected changes.
Warnings
Do not use this page for self-diagnosis or self-medication. Pregnancy, breastfeeding, minors, cancer history, allergies, active disease and concurrent treatments require individual professional evaluation.
Published sources
- 1.Frias JP, et al. NEJM, 2021.
- 2.Jastreboff AM, et al. NEJM, 2022.